期刊文献+
共找到193,823篇文章
< 1 2 250 >
每页显示 20 50 100
基于Midas GTS的某近海深基坑开挖三维有限元数值模拟分析
1
作者 张鹏 邓智平 +1 位作者 王磊 蔡亮亮 《甘肃科学学报》 2024年第1期125-129,共5页
为研究近海深基坑在桩锚支护体系下土体开挖变形规律,考虑水流渗透作用,运用Midas GTS对某深基坑开挖过程进行模拟,并结合已有资料进行分析。结果表明:该深基坑开挖后的第一步为最危险施工步,桩顶土体最大位移为13.97 mm,越往下开挖支... 为研究近海深基坑在桩锚支护体系下土体开挖变形规律,考虑水流渗透作用,运用Midas GTS对某深基坑开挖过程进行模拟,并结合已有资料进行分析。结果表明:该深基坑开挖后的第一步为最危险施工步,桩顶土体最大位移为13.97 mm,越往下开挖支护体系越完善,位移变化越小,实际监测最大位移值为15.36 mm;整个等效地连墙在钢腰梁与锚索位置处向基坑内部变形收缩程度最大,为6.6 mm,符合实际变形规律。Midas GTS能有针对性地指导现实施工阶段,可为基坑监测布置设置点提供参考价值。 展开更多
关键词 深基坑 三维有限元 Midas gtS 基坑开挖
下载PDF
基于Midas GTS/NX的新疆沙漠输水明渠风积土岸坡稳定性分析
2
作者 朱佳宁 王建新 冯成明 《科学技术与工程》 北大核心 2024年第5期2036-2044,共9页
为了准确评估各类工况对新疆沙漠输水明渠风积土岸坡稳定性的影响。通过开展室内土工试验及对该渠道岸坡地质工况进行了调查,采取Midas GTS/NX软件中的强度折减法对输水明渠在未加固和加固两种工况下的竣工期、降雨期、输水期和水位骤降... 为了准确评估各类工况对新疆沙漠输水明渠风积土岸坡稳定性的影响。通过开展室内土工试验及对该渠道岸坡地质工况进行了调查,采取Midas GTS/NX软件中的强度折减法对输水明渠在未加固和加固两种工况下的竣工期、降雨期、输水期和水位骤降4个时期的二维岸坡进行稳定性计算,通过对比岸坡在未加固与加固两个工况下4个时期的整体位移量、等效塑性应变区和安全系数,对岸坡整体稳定及加固效果给出了分析及评价。结果表明:渠道未加固与加固两个工况下4个时期下风积土岸坡均处于稳定状态,安全系数均大于1.30;渠道位于输水期时,坡体前缘水压增加,有效提高渠道岸坡的安全系数,但水位骤降对风积土岸坡稳定性影响最大,降雨次之;未加固时,4个时期的岸坡等效塑性应变区呈圆弧状且已贯通;经加固后,岸坡等效塑性应变区大体沿衬砌呈直线分布,滑移带位移变形得到较好控制,极大程度降低了滑坡灾害发生的可能性。研究结果在一定程度上可以为新疆沙漠风积土输水渠道工程建设提供参考。 展开更多
关键词 Midas gtS/NX 风积土 岸坡稳定性 位移 等效塑性应变
下载PDF
A review of the literature on the use of CRISPR/Cas9 gene therapy to treat hepatocellular carcinoma 被引量:1
3
作者 ELHAM AMJAD RAFAELE PEZZANI BABAK SOKOUTI 《Oncology Research》 SCIE 2024年第3期439-461,共23页
Noncoding RNAs instruct the Cas9 nuclease to site speifillyl cleave DNA in the CRISPR/Cas9 system.Despite the high incidence of hepatocellular carcinoma(HCC),the patient's outcome is poor.As a result of the emerge... Noncoding RNAs instruct the Cas9 nuclease to site speifillyl cleave DNA in the CRISPR/Cas9 system.Despite the high incidence of hepatocellular carcinoma(HCC),the patient's outcome is poor.As a result of the emergence of therapeutic resistance in HCC patients,dlinicians have faced difficulties in treating such tumor.In addition,CRISPR/Cas9 screens were used to identify genes that improve the dlinical response of HCC patients.It is the objective of this article to summarize the current understanding of the use of the CRISPR/Cas9 system for the treatment of cancer,with a particular emphasis on HCC as part of the current state of knowledge.Thus,in order to locate recent developments in oncology research,we examined both the Scopus database and the PubMed database.The ability to selectively interfere with gene expression in combinatorial CRISPR/Cas9 screening can lead to the discovery of new effective HCC treatment regimens by combining clinically approved drugs.Drug resistance can be overcome with the help of the CRISPR/Cas9 system.HCC signature genes and resistance to treatment have been uncovered by genome-scale CRISPR activation screening although this method is not without limitations.It has been extensively examined whether CRISPR can be used as a tool for disease research and gene therapy.CRISPR and its applications to tumor research,particularly in HCC,are examined in this study through a review of the literature. 展开更多
关键词 CRISPR/Cas9 system Gene therapy TUMOR Hepatocellular carcinoma Liver cancer Gene editing
下载PDF
Axial length shortening in myopic children with Stickler syndrome after repeated low-level red-light therapy
4
作者 Xiang-Hua Tang Meng-Ting Yu +2 位作者 Yin Hu Ming-Guang He Xiao Yang 《International Journal of Ophthalmology(English edition)》 SCIE CAS 2023年第10期1712-1717,共6页
AIM:To report the myopia-controlling effect of repeated low-level red-light(RLRL)therapy in patients with Stickler syndrome(STL),an inherited collagenic disease typically presenting with early onset myopia.METHODS:Thr... AIM:To report the myopia-controlling effect of repeated low-level red-light(RLRL)therapy in patients with Stickler syndrome(STL),an inherited collagenic disease typically presenting with early onset myopia.METHODS:Three STL children,aged 3,7,and 11y,received RLRL therapy throughout the follow-up period of 17,3,and 6mo,respectively after exclusion of fundus anomalies.Data on best-corrected visual acuity(BCVA),intraocular pressure,cycloplegic subjective refraction,ocular biometrics,scanning laser ophthalmoscope,optical coherence tomography,genetic testing,systemic disease history,and family history were recorded.RESULTS:At the initiation of the RLRL therapy,the spherical equivalent(SE)of 6 eyes from 3 patients ranged from-3.75 to-20.38 D,axial length(AL)were from 23.88 to 30.68 mm,and BCVA were from 0.4 to 1.0(decimal notation).Myopia progression of all six eyes slowed down after RLRL therapy.AL in five out of the six eyes shortened-0.07 to-0.63 mm.No side effects were observed.CONCLUSION:Three cases of STL whose progression of myopic shift and AL elongation are successfully reduced and even reversed after RLRL therapy. 展开更多
关键词 Stickler syndrome axial length shortening MYOPIA repeated low-level red-light therapy
下载PDF
非小细胞肺癌微卫星(GT/CA)_(n)重复序列多态性的研究进展
5
作者 杨汶峻 傅雨婷 +2 位作者 袁叶琴 刘达 蒋斌元 《肿瘤防治研究》 CAS 2024年第3期195-202,共8页
非小细胞肺癌(NSCLC)是肺癌最主要的组织学类型,患者数量庞大且晚期患者疗效差,现有治疗手段虽取得巨大进展但仍面临挑战。肿瘤的发生伴随大量基因组序列的不稳定,(GT/CA)_(n)重复序列是一种常见的微卫星序列,参与了基因转录和DNA甲基... 非小细胞肺癌(NSCLC)是肺癌最主要的组织学类型,患者数量庞大且晚期患者疗效差,现有治疗手段虽取得巨大进展但仍面临挑战。肿瘤的发生伴随大量基因组序列的不稳定,(GT/CA)_(n)重复序列是一种常见的微卫星序列,参与了基因转录和DNA甲基化等调控过程。现有研究表明,NSCLC中(GT/CA)_(n)重复序列的多态性与EGFR、HO-1和HIF-1α基因的表达密切相关,可作为探索NSCLC发生发展的分子机制、开发诊疗预后分子标志物及相关表观遗传学研究的切入点。本文总结了NSCLC中微卫星(GT/CA)_(n)重复多态性的相关研究,希望能为NSCLC的相关研究提供参考。 展开更多
关键词 非小细胞肺癌 微卫星 (gt/CA)_(n)重复序列 EGFR
下载PDF
Revolutionizing gastric cancer treatment:The potential of immunotherapy
6
作者 Grigorios Christodoulidis Konstantinos Eleftherios Koumarelas Marina Nektaria Kouliou 《World Journal of Gastroenterology》 SCIE CAS 2024年第4期286-289,共4页
Gastric cancer,a prevalent malignancy worldwide,ranks sixth in terms of frequency and third in fatality,causing over a million new cases and 769000 annual deaths.Predominant in Eastern Europe and Eastern Asia,risk fac... Gastric cancer,a prevalent malignancy worldwide,ranks sixth in terms of frequency and third in fatality,causing over a million new cases and 769000 annual deaths.Predominant in Eastern Europe and Eastern Asia,risk factors include family medical history,dietary habits,tobacco use,Helicobacter pylori,and Epstein-Barr virus infections.Unfortunately,gastric cancer is often diagnosed at an advanced stage,leading to a grim prognosis,with a 5-year overall survival rate below 5%.Surgical intervention,particularly with D2 Lymphadenectomy,is the mainstay for early-stage cases but offers limited success.For advanced cases,the National Comprehensive Cancer Network recommends chemotherapy,radiation,and targeted therapy.Emerging immunotherapy presents promise,especially for unresectable or metastatic cases,with strategies like immune checkpoint inhibitors,tumor vaccines,adoptive immunotherapy,and nonspecific immunomodulators.In this Editorial,with regards to the article“Advances and key focus areas in gastric cancer immunotherapy:A comprehensive scientometric and clinical trial review”,we address the advances in the field of immunotherapy in gastric cancer and its future prospects. 展开更多
关键词 IMMUNOtherapy Adaptive immunotherapy Tumor vaccines Chimeric antigen receptor therapy Tumor-infiltrating lymphocytes therapy Natural killer therapy Cytokine-induced killer therapy Engineered T cell receptor therapy Immune checkpoint inhibitors
下载PDF
Combinational therapy with Myc decoy oligodeoxynucleotides encapsulated in nanocarrier and X-irradiation on breast cancer cells
7
作者 BEHROOZ JOHARI MILAD PARVINZAD LEILAN +3 位作者 MAHMOUD GHARBAVI YOUSEF MORTAZAVI ALI SHARAFI HAMED REZAEEJAM 《Oncology Research》 SCIE 2024年第2期309-323,共15页
The Myc gene is the essential oncogene in triple-negative breast cancer(TNBC).This study investigates the synergistic effects of combining Myc decoy oligodeoxynucleotides-encapsulated niosomes-selenium hybrid nanocarr... The Myc gene is the essential oncogene in triple-negative breast cancer(TNBC).This study investigates the synergistic effects of combining Myc decoy oligodeoxynucleotides-encapsulated niosomes-selenium hybrid nanocarriers with X-irradiation exposure on the MDA-MB-468 cell line.Decoy and scramble ODNs for Myc transcription factor were designed and synthesized based on promoter sequences of the Bcl2 gene.The nanocarriers were synthesized by loading Myc ODNs and selenium into chitosan(Chi-Se-DEC),which was then encapsulated in niosome-nanocarriers(NISM@Chi-Se-DEC).FT-IR,DLS,FESEM,and hemolysis tests were applied to confirm its characterization and physicochemical properties.Moreover,cellular uptake,cellular toxicity,apoptosis,cell cycle,and scratch repair assays were performed to evaluate its anticancer effects on cancer cells.All anticancer assessments were repeated under X-ray irradiation conditions(fractionated 2Gy).Physicochemical characteristics of niosomes containing SeNPs and ODNs showed that it is synthesized appropriately.It revealed that the anticancer effect of NISM@Chi-Se-DEC can be significantly improved in combination with X-ray irradiation treatment.It can be concluded that NISM@Chi-Se-DEC nanocarriers have the potential as a therapeutic agent for cancer treatment,particularly in combination with radiation therapy and in-vivo experiments are necessary to confirm the efficacy of this nano-drug. 展开更多
关键词 Combinational therapy Antisense therapy Myc signaling pathway NIOSOMES Radiation therapy SeNPs
下载PDF
Treatment of spinal cord injury with biomaterials and stem cell therapy in non-human primates and humans
8
作者 Ana Milena Silva Olaya Fernanda Martins Almeida +1 位作者 Ana Maria Blanco Martinez Suelen Adriani Marques 《Neural Regeneration Research》 SCIE CAS 2025年第2期343-353,共11页
Spinal cord injury results in the loss of sensory,motor,and autonomic functions,which almost always produces permanent physical disability.Thus,in the search for more effective treatments than those already applied fo... Spinal cord injury results in the loss of sensory,motor,and autonomic functions,which almost always produces permanent physical disability.Thus,in the search for more effective treatments than those already applied for years,which are not entirely efficient,researches have been able to demonstrate the potential of biological strategies using biomaterials to tissue manufacturing through bioengineering and stem cell therapy as a neuroregenerative approach,seeking to promote neuronal recovery after spinal cord injury.Each of these strategies has been developed and meticulously evaluated in several animal models with the aim of analyzing the potential of interventions for neuronal repair and,consequently,boosting functional recovery.Although the majority of experimental research has been conducted in rodents,there is increasing recognition of the importance,and need,of evaluating the safety and efficacy of these interventions in non-human primates before moving to clinical trials involving therapies potentially promising in humans.This article is a literature review from databases(PubMed,Science Direct,Elsevier,Scielo,Redalyc,Cochrane,and NCBI)from 10 years ago to date,using keywords(spinal cord injury,cell therapy,non-human primates,humans,and bioengineering in spinal cord injury).From 110 retrieved articles,after two selection rounds based on inclusion and exclusion criteria,21 articles were analyzed.Thus,this review arises from the need to recognize the experimental therapeutic advances applied in non-human primates and even humans,aimed at deepening these strategies and identifying the advantages and influence of the results on extrapolation for clinical applicability in humans. 展开更多
关键词 BIOENGINEERING BIOMATERIALS cell therapy humans non-human primates spinal cord injury stem cell therapy
下载PDF
Immunotherapy for esophageal cancer:Where are we now and where can we go
9
作者 Yoshiaki Shoji Kazuo Koyanagi +8 位作者 Kohei Kanamori Kohei Tajima Mika Ogimi Yamato Ninomiya Miho Yamamoto Akihito Kazuno Kazuhito Nabeshima Takayuki Nishi Masaki Mori 《World Journal of Gastroenterology》 SCIE CAS 2024年第19期2496-2501,共6页
Immune checkpoint inhibitor therapy has dramatically improved patient prognosis,and thereby transformed the treatment in various cancer types including esophageal squamous cell carcinoma(ESCC)in the past decade.Monocl... Immune checkpoint inhibitor therapy has dramatically improved patient prognosis,and thereby transformed the treatment in various cancer types including esophageal squamous cell carcinoma(ESCC)in the past decade.Monoclonal antibodies that selectively inhibit programmed cell death-1(PD-1)activity has now become standard of care in the treatment of ESCC in metastatic settings,and has a high expectation to provide clinical benefit during perioperative period.Further,anti-cytotoxic T-lymphocyte–associated protein 4(CTLA-4)monoclonal antibody has also been approved in the treatment of recurrent/metastatic ESCC in combination with anti-PD-1 antibody.Well understanding of the existing evidence of immune-based treatments for ESCC,as well as recent clinical trials on various combinations with chemotherapy for different clinical settings including neoadjuvant,adjuvant,and metastatic diseases,may provide future prospects of ESCC treatment for better patient outcomes. 展开更多
关键词 Esophageal cancer IMMUNOtherapy Immune checkpoint inhibitor Programmed cell death-1 Anti-cytotoxic T-lymphocyte-associated protein 4 Neoadjuvant therapy Adjuvant therapy Clinical trials Combination therapy
下载PDF
Pathologically successful conversion hepatectomy for advanced giant hepatocellular carcinoma after multidisciplinary therapy:A case report and review of literature
10
作者 Ju-Hang Chu Lu-Yao Huang +6 位作者 Ya-Ru Wang Jun Li Shi-Long Han Hao Xi Wen-Xue Gao Ying-Yu Cui Ming-Ping Qian 《World Journal of Gastrointestinal Oncology》 SCIE 2024年第4期1647-1659,共13页
BACKGROUND Hepatocellular carcinoma(HCC)is one of the leading causes of death due to its complexity,heterogeneity,rapid metastasis and easy recurrence after surgical resection.We demonstrated that combination therapy ... BACKGROUND Hepatocellular carcinoma(HCC)is one of the leading causes of death due to its complexity,heterogeneity,rapid metastasis and easy recurrence after surgical resection.We demonstrated that combination therapy with transcatheter arterial chemoembolization(TACE),hepatic arterial infusion chemotherapy(HAIC),Epclusa,Lenvatinib and Sintilimab is useful for patients with advanced HCC.CASE SUMMARY A 69-year-old man who was infected with hepatitis C virus(HCV)30 years previously was admitted to the hospital with abdominal pain.Enhanced computed tomography(CT)revealed a low-density mass in the right lobe of the liver,with a volume of 12.9 cm×9.4 cm×15 cm,and the mass exhibited a“fast-in/fast-out”pattern,with extensive filling defect areas in the right branch of the portal vein and an alpha-fetoprotein level as high as 657 ng/mL.Therefore,he was judged to have advanced HCC.During treatment,the patient received three months of Epclusa,three TACE treatments,two HAIC treatments,three courses of sintilimab,and twenty-one months of lenvatinib.In the third month of treatment,the patient developed severe side effects and had to stop immunotherapy,and the Lenvatinib dose had to be halved.Postoperative pathological diagnosis indicated a complete response.The patient recovered well after the operation,and no tumor recurrence was found.CONCLUSION Multidisciplinary conversion therapy for advanced enormous HCC caused by HCV infection has a significant effect.Individualized drug adjustments should be made during any treatment according to the patient's tolerance to treatment. 展开更多
关键词 Hepatocellular therapy Conversion hepatectomy Interventional therapy Epclusa Lenvatinib Sintilimab Case report
下载PDF
Stem cell-based ischemic stroke therapy:Novel modifications and clinical challenges
11
作者 Yuankai Sun Xinchi Jiang Jianqing Gao 《Asian Journal of Pharmaceutical Sciences》 SCIE CAS 2024年第1期18-34,共17页
Ischemic stroke(IS)causes severe disability and high mortality worldwide.Stem cell(SC)therapy exhibits unique therapeutic potential for IS that differs from current treatments.SC’s cell homing,differentiation and par... Ischemic stroke(IS)causes severe disability and high mortality worldwide.Stem cell(SC)therapy exhibits unique therapeutic potential for IS that differs from current treatments.SC’s cell homing,differentiation and paracrine abilities give hope for neuroprotection.Recent studies on SC modification have enhanced therapeutic effects for IS,including gene transfection,nanoparticle modification,biomaterial modification and pretreatment.Thesemethods improve survival rate,homing,neural differentiation,and paracrine abilities in ischemic areas.However,many problems must be resolved before SC therapy can be clinically applied.These issues include production quality and quantity,stability during transportation and storage,as well as usage regulations.Herein,we reviewed the brief pathogenesis of IS,the“multi-mechanism”advantages of SCs for treating IS,various SC modification methods,and SC therapy challenges.We aim to uncover the potential and overcome the challenges of using SCs for treating IS and convey innovative ideas for modifying SCs. 展开更多
关键词 Ischemic stroke Stem cell therapy Stem cell modification Cell therapy challenge
下载PDF
基于Midas GTS分析的深基坑降水开挖变形特性研究
12
作者 温世聪 周汇智 《工程建设与设计》 2024年第6期16-19,共4页
基于Midas GTS软件对广州某深基坑开挖过程进行数值模拟,考虑渗流作用的影响,对比分析了两种情况下基坑开挖过程中周边地表沉降变形、围护结构水平位移的变化规律,并与现场地面沉降调查结果进行比较。结果表明,地下水渗流作用在基坑降... 基于Midas GTS软件对广州某深基坑开挖过程进行数值模拟,考虑渗流作用的影响,对比分析了两种情况下基坑开挖过程中周边地表沉降变形、围护结构水平位移的变化规律,并与现场地面沉降调查结果进行比较。结果表明,地下水渗流作用在基坑降水开挖过程中有显著影响。 展开更多
关键词 基坑降水 数值模拟 Midas gtS 变形特性
下载PDF
基于MIDAS GTS的顶管下穿施工对高铁桥梁影响的数值分析
13
作者 陈祯 《城市道桥与防洪》 2024年第5期227-230,M0020,共5页
为研究新建天然气管道下穿施工对京津城际铁路杨村特大桥的影响,以高压天然气管道穿越京津城际铁路防护套管工程为背景,对下穿京津城际铁路杨村特大桥段顶管施工进行设计,通过运用MIDAS GTS有限元软件对顶管施工下穿高铁桥梁进行有限元... 为研究新建天然气管道下穿施工对京津城际铁路杨村特大桥的影响,以高压天然气管道穿越京津城际铁路防护套管工程为背景,对下穿京津城际铁路杨村特大桥段顶管施工进行设计,通过运用MIDAS GTS有限元软件对顶管施工下穿高铁桥梁进行有限元数值分析,得出了采取顶管下穿高铁桥梁施工,会引起铁路桥墩的扰动和变形,进而引起结构受力的变化。在揭示了施工过程前后地层应力分布变化规律后,提出相关改进建议。 展开更多
关键词 顶管 下穿施工 MIDAS gtS 数值模拟 受力变形
下载PDF
The Role of Music Therapy in Supporting Intellectually Disabled Youth in Senegal
14
作者 Raymond Birane Youm Kadidiatou Diarra +1 位作者 Mathias Pouye Jean Augustin Diégane Tine 《Health》 2024年第5期521-534,共14页
Introduction: Music therapy is a practice for helping and supporting people with intellectual and relational difficulties. This study illustrated the benefits of music therapy for young people living with intellectual... Introduction: Music therapy is a practice for helping and supporting people with intellectual and relational difficulties. This study illustrated the benefits of music therapy for young people living with intellectual disabilities (YLID) in an African context. Methodology: This study investigated six young individuals with intellectual disabilities who had undergone three years of music therapy. They were participants in the inclusive non-academic training program at the National School of Arts in Dakar from 2017 to 2019. Data collection utilized individual interviews with the youths, evaluation grids from teachers and psychiatrists. Guardians provided informed consent along with the assent of the young participants. Results: The six young were aged between 18 and 30 years old, with an average age of 24.6 years. Four of the YLID were male. Three young people with intellectual disabilities had delayed psychomotor development. Observations revealed the beneficial influence of music therapy on the health and well-being of young individuals. Music played a role in alleviating stress and anxiety among youth with intellectual disabilities (YLID), enhancing their mood and mental health. It assisted in navigating challenging situations and heightened alertness among YLID. Additionally, music therapy contributed to improvements in dyslexia, fine and gross motor skills, and memory development among intellectually disabled youth, ultimately facilitating their integration into society. Conclusion: In light of our results, music therapy makes a major contribution to the empowerment of YLID. Engaging in musical activities helps young people connect with others through instrumental expression and a sense of accomplishment. By facilitating music therapy, it becomes possible to combat discrimination and stigmatization, thus promoting the social inclusion of intellectually disabled youth. Therefore, it is important to promote music therapy in Senegal to meet the needs of YLID. 展开更多
关键词 Music therapy YOUNG Intellectual Disabilities Senegal
下载PDF
Establishment of NaLuF_(4):15%Tb-based low dose X-PDT agent and its application on efficient antitumor therapy
15
作者 Yi Tian Zhiguang Fu +7 位作者 Xiaosheng Zhu Chunjing Zhan Jinwei Hu Li Fan Chaojun Song Qian Yang Yu Wang Mei Shi 《International Journal of Minerals,Metallurgy and Materials》 SCIE EI CAS CSCD 2024年第3期599-610,共12页
X-ray excited photodynamic therapy(X-PDT)is the bravo answer of photodynamic therapy(PDT)for deep-seated tumors,as it employs X-ray as the irradiation source to overcome the limitation of light penetration depth.Howev... X-ray excited photodynamic therapy(X-PDT)is the bravo answer of photodynamic therapy(PDT)for deep-seated tumors,as it employs X-ray as the irradiation source to overcome the limitation of light penetration depth.However,high X-ray irradiation dose caused organ lesions and side effects became the major barrier to X-PDT application.To address this issue,this work employed a classic-al co-precipitation reaction to synthesize NaLuF_(4):15%Tb^(3+)(NLF)with an average particle size of(23.48±0.91)nm,which was then coupled with the photosensitizer merocyanine 540(MC540)to form the X-PDT system NLF-MC540 with high production of singlet oxygen.The system could induce antitumor efficacy to about 24%in relative low dose X-ray irradiation range(0.1-0.3 Gy).In vivo,when NLF-MC540 irradiated by 0.1 Gy X-ray,the tumor inhibition percentage reached 89.5%±5.7%.The therapeutic mechanism of low dose X-PDT was found.A significant increase of neutrophils in serum was found on the third day after X-PDT.By immunohistochemical staining of tumor sections,the Ly6G^(+),CD8^(+),and CD11c^(+)cells infiltrated in the tumor microenvironment were studied.Utilizing the bilat-eral tumor model,the NLF-MC540 with 0.1 Gy X-ray irradiation could inhibit both the primary tumor and the distant tumor growth.De-tected by enzyme linked immunosorbent assay(ELISA),two cytokines IFN-γand TNF-αin serum were upregulated 7 and 6 times than negative control,respectively.Detected by enzyme linked immune spot assay(ELISPOT),the number of immune cells attributable to the IFN-γand TNF-αlevels in the group of low dose X-PDT were 14 and 6 times greater than that in the negative control group,respectively.Thus,it conclude that low dose X-PDT system could successfully upregulate the levels of immune cells,stimulate the secretion of cy-tokines(especially IFN-γand TNF-α),activate antitumor immunity,and finally inhibit colon tumor growth. 展开更多
关键词 X-ray excited photodynamic therapy singlet oxygen low dose X-Ray irradiation efficient antitumor therapy anti-tumor immunity
下载PDF
Sequential neoadjuvant chemotherapy using pegylated liposomal doxorubicin and cyclophosphamide followed by taxanes with complete trastuzumab and pertuzumab treatment for HER2-positive breast cancer: A phase Ⅱ single-arm study
16
作者 Yaping Yang Liang Jin +11 位作者 Yudong Li Nanyan Rao Chang Gong Shunrong Li Jiannan Wu Jinghua Zhao Linxiaoxiao Ding Fengxia Gan Jun Zhang Ruifa Feng Zhenzhen Liu Qiang Liu 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2024年第1期55-65,共11页
Objective: Despite cardiotoxicity overlap, the trastuzumab/pertuzumab and anthracycline combination remains crucial due to significant benefits. Pegylated liposomal doxorubicin(PLD), a less cardiotoxic anthracycline, ... Objective: Despite cardiotoxicity overlap, the trastuzumab/pertuzumab and anthracycline combination remains crucial due to significant benefits. Pegylated liposomal doxorubicin(PLD), a less cardiotoxic anthracycline, was evaluated for efficacy and cardiac safety when combined with cyclophosphamide and followed by taxanes with trastuzumab/pertuzumab in human epidermal growth factor receptor-2(HER2)-positive early breast cancer(BC).Methods: In this multicenter, phase II study, patients with confirmed HER2-positive early BC received four cycles of PLD(30-35 mg/m^(2)) and cyclophosphamide(600 mg/m^(2)), followed by four cycles of taxanes(docetaxel,90-100 mg/m^(2) or nab-paclitaxel, 260 mg/m^(2)), concomitant with eight cycles of trastuzumab(8 mg/kg loading dose,then 6 mg/kg) and pertuzumab(840 mg loading dose, then 420 mg) every 3 weeks. The primary endpoint was total pathological complete response(tp CR, yp T0/is yp N0). Secondary endpoints included breast p CR(bp CR),objective response rate(ORR), disease control rate, rate of breast-conserving surgery(BCS), and safety(with a focus on cardiotoxicity).Results: Between May 27, 2020 and May 11, 2022, 78 patients were treated with surgery, 42(53.8%) of whom had BCS. After neoadjuvant therapy, 47 [60.3%, 95% confidence interval(95% CI), 48.5%-71.2%] patients achieved tp CR, and 49(62.8%) achieved bp CR. ORRs were 76.9%(95% CI, 66.0%-85.7%) and 93.6%(95% CI,85.7%-97.9%) after 4-cycle and 8-cycle neoadjuvant therapy, respectively. Nine(11.5%) patients experienced asymptomatic left ventricular ejection fraction(LVEF) reductions of ≥10% from baseline, all with a minimum value of >55%. No treatment-related abnormal cardiac function changes were observed in mean N-terminal pro-BNP(NT-pro BNP), troponin I, or high-sensitivity troponin.Conclusions: This dual HER2-blockade with sequential polychemotherapy showed promising activity with rapid tumor regression in HER2-positive BC. Importantly, this regimen showed an acceptable safety profile,especially a low risk of cardiac events, suggesting it as an attractive treatment approach with a favorable risk-benefit balance. 展开更多
关键词 Breast cancer HER2-positive breast cancer dual HER2 blockade neoadjuvant therapy sequential therapy
下载PDF
Dual-Fields Rotational Total Skin Electron Therapy: Investigation and Implementation
17
作者 M. Ming Xu Iris Rusu Richard P. Garza 《International Journal of Medical Physics, Clinical Engineering and Radiation Oncology》 2024年第1期1-15,共15页
Purpose: To present a protocol of a dual-field rotational (DFR) total skin electron therapy (TSET) and to provide an assessment of clinical implementation, dosimetry properties, and skin dose evaluation. Methods and M... Purpose: To present a protocol of a dual-field rotational (DFR) total skin electron therapy (TSET) and to provide an assessment of clinical implementation, dosimetry properties, and skin dose evaluation. Methods and Materials: The DFR-TSET combined the Stanford 6-field and McGill rotational methods. Dual 6 MeV electron beams in high dose total skin electron mode were used for DFR-TSET on a commercial linac. Beam profiles and dosimetric properties were measured using solid phantoms. The dose rate at expanded source-to-surface distance (SSD) was a combination of static rate and rotational rate. In vivo dosimetry of patient skin was performed on patients’ skin using film, metal oxide semiconductor field-effect transistors (MOSFET), and optically stimulated luminescent dosimeters (OSLD). Results: Dual field rotational total skin electron therapy exhibited good (≤±10%) uniformity in the beam profiles in the vertical direction at an extended SSD of 332 cm with a gantry angulation of ±20˚ deviated from the horizontal direction. In-vivo measurements confirmed acceptable uniformity of the patients’ total body surfaces and revealed anatomically self-blocked or shielded areas where underdosing occurred. Conclusions: The clinical implementation of DFR-TSET effectively utilizes the special mode on a linac. This technique provides short beam-on times, uniform dose distribution, large treatment field, and reduced dose of x-ray contamination to the patients. In-vivo measurements indicate satisfactory delivery and dose uniformity of the prescribed dose. Electron boost fields are recommended at normal SSDs to address underdosed areas. 展开更多
关键词 Total Skin Electron therapy Stanford 6 Field McGill Rotation therapy In-Vivo Dosimetry
下载PDF
PRaG 3.0 therapy for human epidermal growth factor receptor 2-positive metastatic pancreatic ductal adenocarcinoma:A case report
18
作者 Yue-Hong Kong Mei-Ling Xu +10 位作者 Jun-Jun Zhang Guang-Qiang Chen Zhi-Hui Hong Hong Zhang Xiao-Xiao Dai Yi-Fu Ma Xiang-Rong Zhao Chen-Yang Zhang Rong-Zheng Chen Peng-Fei Xing Li-Yuan Zhang 《World Journal of Gastroenterology》 SCIE CAS 2024年第9期1237-1249,共13页
BACKGROUND Pancreatic ductal adenocarcinoma(PDAC)is a highly fatal disease with limited effective treatment especially after first-line chemotherapy.The human epidermal growth factor receptor 2(HER-2)immunohistochemis... BACKGROUND Pancreatic ductal adenocarcinoma(PDAC)is a highly fatal disease with limited effective treatment especially after first-line chemotherapy.The human epidermal growth factor receptor 2(HER-2)immunohistochemistry(IHC)positive is associated with more aggressive clinical behavior and shorter overall survival in PDAC.CASE SUMMARY We present a case of multiple metastatic PDAC with IHC mismatch repair proficient but HER-2 IHC weakly positive at diagnosis that didn’t have tumor regression after first-line nab-paclitaxel plus gemcitabine and PD-1 inhibitor treatment.A novel combination therapy PRaG 3.0 of RC48(HER2-antibody-drug conjugate),radio-therapy,PD-1 inhibitor,granulocyte-macrophage colony-stimulating factor and interleukin-2 was then applied as second-line therapy and the patient had confirmed good partial response with progress-free-survival of 6.5 months and overall survival of 14.2 month.She had not developed any grade 2 or above treatment-related adverse events at any point.Percentage of peripheral CD8^(+) Temra and CD4^(+) Temra were increased during first two activation cycles of PRaG 3.0 treatment containing radiotherapy but deceased to the baseline during the maintenance cycles containing no radiotherapy.CONCLUSION PRaG 3.0 might be a novel strategy for HER2-positive metastatic PDAC patients who failed from previous first-line approach and even PD-1 immunotherapy but needs more data in prospective trials. 展开更多
关键词 Pancreatic ductal adenocarcinoma PRaG 3.0 therapy Human epidermal growth factor receptor 2 Novel combination therapy Case report
下载PDF
Discontinuation of therapy in inflammatory bowel disease: Current views
19
作者 Antonio Meštrović Marko Kumric Josko Bozic 《World Journal of Clinical Cases》 SCIE 2024年第10期1718-1727,共10页
The timely introduction and adjustment of the appropriate drug in accordance with previously well-defined treatment goals is the foundation of the approach in the treatment of inflammatory bowel disease(IBD).The thera... The timely introduction and adjustment of the appropriate drug in accordance with previously well-defined treatment goals is the foundation of the approach in the treatment of inflammatory bowel disease(IBD).The therapeutic approach is still evolving in terms of the mechanism of action but also in terms of the possibility of maintaining remission.In patients with achieved long-term remission,the question of de-escalation or discontinuation of therapy arises,considering the possible side effects and economic burden of long-term therapy.For each of the drugs used in IBD(5-aminosalycaltes,immunomodulators,biological drugs,small molecules)there is a risk of relapse.Furthermore,studies show that more than 50%of patients who discontinue therapy will relapse.Based on the findings of large studies and meta-analysis,relapse of disease can be expected in about half of the patients after therapy withdrawal,in case of monotherapy with aminosalicylates,immunomodulators or biological therapy.However,longer relapse-free periods are recorded with withdrawal of medication in patients who had previously been on combination therapies immunomodulators and anti-tumor necrosis factor.It needs to be stressed that randomised clinical trials regarding withdrawal from medications are still lacking.Before making a decision on discontinuation of therapy,it is important to distinguish potential candidates and predictive factors for the possibility of disease relapse.Fecal calprotectin level has currently been identified as the strongest predictive factor for relapse.Several other predictive factors have also been identified,such as:High Crohn's disease activity index or Harvey Bradshaw index,younger age(<40 years),longer disease duration(>40 years),smoking,young age of disease onset,steroid use 6-12 months before cessation.An important factor in the decision to withdraw medication is the success of re-treatment with the same or other drugs.The decision to discontinue therapy must be based on individual approach,taking into account the severity,extension,and duration of the disease,the possibility of side adverse effects,the risk of relapse,and patient’s preferences. 展开更多
关键词 Inflammatory bowel disease therapy discontinuation therapy de-escalation Ulcerative colitis Crohn’s disease
下载PDF
Impact of Action Observation Therapy along with Usual Physiotherapy Intervention of Individual with Alzheimer’s Disease
20
作者 Zahid Bin Sultan Nahid Faruq Ahmed +4 位作者 Tuhin Ahammed Md Kutub Uddin Md Sirazul Islam S M Maruf Hossain Sajib Md Rafiqul Islam 《Advances in Alzheimer's Disease》 CAS 2024年第1期1-10,共10页
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by cognitive impairments in the initial stage, which lead to severe cognitive dysfunction in the later stage. Action observation therapy (AOT) is... Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by cognitive impairments in the initial stage, which lead to severe cognitive dysfunction in the later stage. Action observation therapy (AOT) is a multisensory cognitive rehabilitation technique where the patient initially observes the actions and then tries to perform. The study aimed to examine the impact of AOT along with usual physiotherapy interventions to reduce depression, improve cognition and balance of a patient with AD. A 67 years old patient with AD was selected for this study because the patient has been suffering from depression, dementia, and physical dysfunction along with some other health conditions like diabetes and hypertension. Before starting intervention, a baseline assessment was done through the Beck Depression Inventory (BDI) tool, the Mini-Cog Scale, and the Berg Balance Scale (BBS). The patient received 12 sessions of AOT along with usual physiotherapy interventions thrice a week for four weeks, which included 45 minutes of each session. After four weeks of intervention, the patient demonstrated significant improvement in depression, cognition, and balance, whereas the BDI score declined from moderate 21/63 to mild 15/63 level of depression. The Mini-Cog score improved from 2/5 to 4/5, and the BBS score increased from 18/56 to 37/56. It is concluded that AOT along with usual physiotherapy intervention helps to reduce depression, improve cognition and balance of people with AD. 展开更多
关键词 Alzheimer’s Disease Action Observation therapy Physiotherapy Intervention
下载PDF
上一页 1 2 250 下一页 到第
使用帮助 返回顶部